报告题目：PET Probe Development and Application - Impact of Mitochondria Imaging Probe

时间：11月16日上午9:00 地点：化学楼二楼会议室

报告人：Hideo Tsukada, Ph.D.

Abstract

FDG-PET is a unique technique for quantitative imaging of regional cerebral metabolic rate of glucose (rCMRglc) in living brain. However, ¹⁸F-FDG was taken up into not only normal tissues but also inflammatory regions with microglial activation which humper the accurate diagnoses of brain diseases. To solve this problem, we recently succeeded to develop ¹⁸F-BCPP-EF, a novel PET probe for mitochondrial complex 1 (MC-1) [1], and several preclinical researches with ¹⁸F-BCPP-EF were conducted using an animal PET scanner to assess the changes in MC-I activity in the aging process [2], ischemic [3], Alzheimer disease [4], and Parkinson disease models [5,6] of monkeys. In addition, we have started the clinical PET researches in corroboration with several academic and industrial groups. These results strongly suggested that MC-I imaging using ¹⁸F-BCPP-EF could be a useful imaging index superior to ¹⁸F-FDG.

References

1)     Tsukada H, et al. J Nucl Med. 2014;55:473-480.

2)     Tsukada H, et al. Eur J Nucl Med Mol Imaging. 2014;41:755-763.

3)     Tsukada H, et al. J Cereb Blood Flow Metab. 2014;34:708-714.

4)     Tsukada H, et al. Eur J Nucl Med Mol Imaging. 2014;41:2127-2136.

5)     Tsukada H, et al. J Nucl Med. 2016;57:950-953.

6)     Kanazawa M, Tsukada H, et al. J Nucl Med. 2017;58:1111-1116.

Biography

Dr. Hideo Tsukada is the manager of PET Center, Central Research Laboratory of Hamamatsu Photonics K.K.. He got his Ph.D in Pharmacological Sciences in 1987 at Shizuoka College of Pharmacy. He was visiting researcher in Uppsala University PET Center, Sweden from 1990 to 91. He is serving as the visiting professor in University of Shizuoka, School of Pharmaceutical Sciences from 2006, and Hamamatsu University School of Medicine from 2007, the board member of The Japanese Society of Molecular Imaging from 2008, The Japanese Society of Chemical Biology from 2009, and The Japanese Society of Neuropsychopharmacology from 2013. He has published more than 250 papers in reputed journals, being awarded by the Society for Nuclear Medicine in 2009, and Japan Molecular Imaging Award in 2010.